European Journal of Epidemiology最新文献

筛选
英文 中文
A phenome-wide association and factorial Mendelian randomization study on the repurposing of uric acid-lowering drugs for cardiovascular outcomes. 关于降尿酸药物重新用于心血管治疗的全表象关联和因子孟德尔随机研究。
IF 7.7 1区 医学
European Journal of Epidemiology Pub Date : 2024-08-01 Epub Date: 2024-07-11 DOI: 10.1007/s10654-024-01138-0
Lijuan Wang, Ines Mesa-Eguiagaray, Harry Campbell, James F Wilson, Veronique Vitart, Xue Li, Evropi Theodoratou
{"title":"A phenome-wide association and factorial Mendelian randomization study on the repurposing of uric acid-lowering drugs for cardiovascular outcomes.","authors":"Lijuan Wang, Ines Mesa-Eguiagaray, Harry Campbell, James F Wilson, Veronique Vitart, Xue Li, Evropi Theodoratou","doi":"10.1007/s10654-024-01138-0","DOIUrl":"10.1007/s10654-024-01138-0","url":null,"abstract":"<p><p>Uric acid has been linked to various disease outcomes. However, it remains unclear whether uric acid-lowering therapy could be repurposed as a treatment for conditions other than gout. We first performed both observational phenome-wide association study (Obs-PheWAS) and polygenic risk score PheWAS (PRS-PheWAS) to identify associations of uric acid levels with a wide range of disease outcomes. Then, trajectory analysis was conducted to explore temporal progression patterns of the observed disease outcomes. Finally, we investigated whether uric acid-lowering drugs could be repurposed using a factorial Mendelian randomization (MR) study design. A total of 41 overlapping phenotypes associated with uric acid levels were identified by both Obs- and PRS- PheWASs, primarily cardiometabolic diseases. The trajectory analysis illustrated how elevated uric acid levels contribute to cardiometabolic diseases, and finally death. Meanwhile, we found that uric acid-lowering drugs exerted a protective role in reducing the risk of coronary atherosclerosis (OR = 0.96, 95%CI: 0.93, 1.00, P = 0.049), congestive heart failure (OR = 0.64, 95%CI: 0.42, 0.99, P = 0.043), occlusion of cerebral arteries (OR = 0.93, 95%CI: 0.87, 1.00, P = 0.044) and peripheral vascular disease (OR = 0.60, 95%CI: 0.38, 0.94, P = 0.025). Furthermore, the combination of uric acid-lowering therapy (e.g. xanthine oxidase inhibitors) with antihypertensive treatment (e.g. calcium channel blockers) exerted additive effects and was associated with a 6%, 8%, 8%, 10% reduction in risk of coronary atherosclerosis, heart failure, occlusion of cerebral arteries and peripheral vascular disease, respectively. Our findings support a role of elevated uric acid levels in advancing cardiovascular dysfunction and identify potential repurposing opportunities for uric acid-lowering drugs in cardiovascular treatment.</p>","PeriodicalId":11907,"journal":{"name":"European Journal of Epidemiology","volume":" ","pages":"869-880"},"PeriodicalIF":7.7,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11410910/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141589991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multi-biobank Mendelian randomization analyses identify opposing pathways in plasma low-density lipoprotein-cholesterol lowering and gallstone disease. 多生物库孟德尔随机分析确定了降低血浆低密度脂蛋白胆固醇与胆石症的对立途径。
IF 7.7 1区 医学
European Journal of Epidemiology Pub Date : 2024-08-01 Epub Date: 2024-07-15 DOI: 10.1007/s10654-024-01141-5
Guoyi Yang, Amy M Mason, Dipender Gill, C Mary Schooling, Stephen Burgess
{"title":"Multi-biobank Mendelian randomization analyses identify opposing pathways in plasma low-density lipoprotein-cholesterol lowering and gallstone disease.","authors":"Guoyi Yang, Amy M Mason, Dipender Gill, C Mary Schooling, Stephen Burgess","doi":"10.1007/s10654-024-01141-5","DOIUrl":"10.1007/s10654-024-01141-5","url":null,"abstract":"<p><p>Plasma low-density lipoprotein (LDL)-cholesterol is positively associated with coronary artery disease risk while biliary cholesterol promotes gallstone formation. Different plasma LDL-cholesterol lowering pathways may have distinct effects on biliary cholesterol and thereby gallstone disease risk. We conducted a Mendelian randomization (MR) study using data from the UK Biobank (30,547 gallstone disease cases/336,742 controls), FinnGen (34,461 cases/301,383 controls) and Biobank Japan (9,305 cases/168,253 controls). We first performed drug-target MR analyses substantiated by colocalization to investigate the effects of plasma LDL-cholesterol lowering therapies on gallstone disease risk. We then performed clustered MR analyses and pathway analyses to identify distinct mechanisms underlying the association of plasma LDL-cholesterol with gallstone disease risk. For a 1-standard deviation reduction in plasma LDL-cholesterol, genetic mimics of statins were associated with lower gallstone disease risk (odds ratio 0.72 [95% confidence interval 0.62, 0.83]), but genetic mimics of PCSK9 inhibitors and targeting apolipoprotein B were associated with higher risk (1.11 [1.03, 1.19] and 1.23 [1.13, 1.35]). The association for statins was supported by colocalization (posterior probability 98.7%). Clustered MR analyses identified variant clusters showing opposing associations of plasma LDL-cholesterol with gallstone disease risk, with some evidence for ancestry-and sex-specific associations. Among variants lowering plasma LDL-cholesterol, those associated with lower gallstone disease risk were mapped to glycosphingolipid biosynthesis pathway, while those associated with higher risk were mapped to pathways relating to plasma lipoprotein assembly, remodelling, and clearance and ATP-binding cassette transporters. This MR study provides genetic evidence that different plasma LDL-cholesterol lowering pathways have opposing effects on gallstone disease risk.</p>","PeriodicalId":11907,"journal":{"name":"European Journal of Epidemiology","volume":" ","pages":"857-867"},"PeriodicalIF":7.7,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11410903/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141619692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Using the global randomization test as a Mendelian randomization falsification test for the exclusion restriction assumption. 使用全局随机化检验作为排除限制假设的孟德尔随机化证伪检验。
IF 7.7 1区 医学
European Journal of Epidemiology Pub Date : 2024-08-01 Epub Date: 2024-02-29 DOI: 10.1007/s10654-024-01097-6
Louise A C Millard, George Davey Smith, Kate Tilling
{"title":"Using the global randomization test as a Mendelian randomization falsification test for the exclusion restriction assumption.","authors":"Louise A C Millard, George Davey Smith, Kate Tilling","doi":"10.1007/s10654-024-01097-6","DOIUrl":"10.1007/s10654-024-01097-6","url":null,"abstract":"<p><p>Mendelian randomization may give biased causal estimates if the instrument affects the outcome not solely via the exposure of interest (violating the exclusion restriction assumption). We demonstrate use of a global randomization test as a falsification test for the exclusion restriction assumption. Using simulations, we explored the statistical power of the randomization test to detect an association between a genetic instrument and a covariate set due to (a) selection bias or (b) horizontal pleiotropy, compared to three approaches examining associations with individual covariates: (i) Bonferroni correction for the number of covariates, (ii) correction for the effective number of independent covariates, and (iii) an r<sup>2</sup> permutation-based approach. We conducted proof-of-principle analyses in UK Biobank, using CRP as the exposure and coronary heart disease (CHD) as the outcome. In simulations, power of the randomization test was higher than the other approaches for detecting selection bias when the correlation between the covariates was low (r<sup>2</sup> < 0.1), and at least as powerful as the other approaches across all simulated horizontal pleiotropy scenarios. In our applied example, we found strong evidence of selection bias using all approaches (e.g., global randomization test p < 0.002). We identified 51 of the 58 CRP genetic variants as horizontally pleiotropic, and estimated effects of CRP on CHD attenuated somewhat to the null when excluding these from the genetic risk score (OR = 0.96 [95% CI: 0.92, 1.00] versus 0.97 [95% CI: 0.90, 1.05] per 1-unit higher log CRP levels). The global randomization test can be a useful addition to the MR researcher's toolkit.</p>","PeriodicalId":11907,"journal":{"name":"European Journal of Epidemiology","volume":" ","pages":"843-855"},"PeriodicalIF":7.7,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11410989/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139989690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cognitive ability, education, height and body mass index in relation to risk of schizophrenia and mortality following its diagnosis 认知能力、教育程度、身高和体重指数与精神分裂症风险和确诊后死亡率的关系
IF 13.6 1区 医学
European Journal of Epidemiology Pub Date : 2024-07-27 DOI: 10.1007/s10654-024-01140-6
Terese Sara Høj Jørgensen, Ida Kim Wium-Andersen, Marie Kim Wium-Andersen, Maarten Pieter Rozing, Martin Balslev Jørgensen, Thorkild IA Sørensen, Merete Osler
{"title":"Cognitive ability, education, height and body mass index in relation to risk of schizophrenia and mortality following its diagnosis","authors":"Terese Sara Høj Jørgensen, Ida Kim Wium-Andersen, Marie Kim Wium-Andersen, Maarten Pieter Rozing, Martin Balslev Jørgensen, Thorkild IA Sørensen, Merete Osler","doi":"10.1007/s10654-024-01140-6","DOIUrl":"https://doi.org/10.1007/s10654-024-01140-6","url":null,"abstract":"<p>This study examines the hypotheses that the traits of higher IQ, longer education and taller height are associated with lower risk of death as compared to traits of low IQ, short education, and short height in men with schizophrenia compared to men without schizophrenia. In total, 937,919 men born 1939-59 and 1983–1997 with information from conscription were followed for incident schizophrenia in Danish registries. Higher levels of cognitive ability, longer education, and taller height were associated with fewer cases of schizophrenia. In a sub-sample of 652,368 men with information on body mass index, underweight was associated with more and overweight and obesity were associated with fewer cases of schizophrenia compared with normal weight. Higher cognitive ability, longer education, and taller height were associated with fewer deaths from both natural and unnatural causes in both men with and without schizophrenia. Underweight was associated with more deaths from natural and unnatural causes, whereas overweight and obesity were associated with more deaths from natural causes and fewer deaths from unnatural causes in both groups of men. Due to interaction, tall height and long educational duration were associated with fewer deaths from natural causes, and obesity was associated with fewer deaths from unnatural causes among men with schizophrenia compared to men without. In conclusion, traits in young adulthood are associated with higher mortality in men with and without schizophrenia, but traits of long educational duration and obesity seem to be especially important for lower mortality in men with schizophrenia.</p>","PeriodicalId":11907,"journal":{"name":"European Journal of Epidemiology","volume":"47 1","pages":""},"PeriodicalIF":13.6,"publicationDate":"2024-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141769133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sex hormone-binding globulin may explain sex differences for glucose homeostasis and incidence of type 2 diabetes: the KORA study 性激素结合球蛋白可解释葡萄糖稳态和 2 型糖尿病发病率的性别差异:KORA 研究
IF 13.6 1区 医学
European Journal of Epidemiology Pub Date : 2024-07-02 DOI: 10.1007/s10654-024-01136-2
Hamidreza Raeisi-Dehkordi, Mojgan Amiri, Wolfgang Rathmann, Tanja Zeller, Jerzy Adamski, Arjola Bano, Yvonne T. van der Schouw, Barbara Thorand, Taulant Muka, Jana Nano
{"title":"Sex hormone-binding globulin may explain sex differences for glucose homeostasis and incidence of type 2 diabetes: the KORA study","authors":"Hamidreza Raeisi-Dehkordi, Mojgan Amiri, Wolfgang Rathmann, Tanja Zeller, Jerzy Adamski, Arjola Bano, Yvonne T. van der Schouw, Barbara Thorand, Taulant Muka, Jana Nano","doi":"10.1007/s10654-024-01136-2","DOIUrl":"https://doi.org/10.1007/s10654-024-01136-2","url":null,"abstract":"<p>Research has indicated that sex hormone-binding globulin (SHBG) is associated with glucose homeostasis and may play a role in the etiology of type 2 diabetes (T2D). While it is unclear whether SHBG may mediate sex differences in glucose control and subsequently, incidence of T2D. We used observational data from the German population-based KORA F4 study (<i>n</i> = 1937, mean age: 54 years, 41% women) and its follow-up examination KORA FF4 (median follow-up 6.5 years, <i>n</i> = 1387). T2D was initially assessed by self-report and validated by contacting the physicians and/ or reviewing the medical charts. Mediation analyses were performed to assess the role of SHBG in mediating the association between sex (women vs. men) and glucose- and insulin-related traits (cross-sectional analysis) and incidence of T2D (longitudinal analysis). After adjustment for confounders, (model 1: adjusted for age; model 2: model 1 + smoking + alcohol consumption + physical activity), women had lower fasting glucose levels compared to men (β = -4.94 (mg/dl), 95% CI: -5.77, -4.11). SHBG levels were significantly higher in women than in men (β = 0.47 (nmol/l), 95% CI:0.42, 0.51). Serum SHBG may mediate the association between sex and fasting glucose levels with a proportion mediated (PM) of 30% (CI: 22–41%). Also, a potential mediatory role of SHBG was observed for sex differences in incidence of T2D (PM = 95% and 63% in models 1 and 2, respectively). Our novel findings suggest that SHBG may partially explain sex-differences in glucose control and T2D incidence.</p>","PeriodicalId":11907,"journal":{"name":"European Journal of Epidemiology","volume":"61 1","pages":""},"PeriodicalIF":13.6,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141489525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trends in incidence and mortality of early-onset cancer in Germany between 1999 and 2019. 1999 年至 2019 年德国早发性癌症的发病率和死亡率趋势。
IF 7.7 1区 医学
European Journal of Epidemiology Pub Date : 2024-07-01 Epub Date: 2024-05-31 DOI: 10.1007/s10654-024-01134-4
Dina Voeltz, Kira Baginski, Claudia Hornberg, Annika Hoyer
{"title":"Trends in incidence and mortality of early-onset cancer in Germany between 1999 and 2019.","authors":"Dina Voeltz, Kira Baginski, Claudia Hornberg, Annika Hoyer","doi":"10.1007/s10654-024-01134-4","DOIUrl":"10.1007/s10654-024-01134-4","url":null,"abstract":"<p><p>Evidence on the recent temporal trend in the incidence and mortality of early-onset cancer, i.e., cancer diagnosed at ages of < 50 years, in Germany is scarce. To estimate the temporal trend in the incidence and mortality of early-onset cancer in Germany between 1999 and 2019. Input data were obtained from the Centre for Cancer Registry Data (Zentrum für Krebsregisterdaten, ZfKD). The analysis comprised all ages until 50 years and all types of cancer classified by the International Classification of Diseases (ICD-10)-codes C00-C97 (excl. C44). Temporal trends were estimated using negative binomial regression, differentiated by sex and cancer type. Between 1999 and 2019 in Germany, we observed stable or slightly increasing trends (0% and 1%) in the incidence of all early-onset cancers combined (C00-C97) for men and women, respectively, and strict declines in the mortality for both, men and women (-2% and - 3%). However, the trends differ largely with respect to sex and the individual cancer types. Early-onset cancer should be closely monitored to see whether stable and decreasing trends in the incidence and mortality continue. Knowing that despite decreasing incidence, the prevalence of a disease can rise due to their interplay with mortality, we recommend to maintain precise surveillance, efforts in prevention and early detection, as well as appropriate investments into healthcare resources, research and development.</p>","PeriodicalId":11907,"journal":{"name":"European Journal of Epidemiology","volume":" ","pages":"827-837"},"PeriodicalIF":7.7,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11343808/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141179043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction: Trends in incidence and mortality of early-onset cancer in Germany between 1999 and 2019. 更正:1999 年至 2019 年德国早发性癌症的发病率和死亡率趋势。
IF 7.7 1区 医学
European Journal of Epidemiology Pub Date : 2024-07-01 DOI: 10.1007/s10654-024-01143-3
Dina Voeltz, Kira Baginski, Claudia Hornberg, Annika Hoyer
{"title":"Correction: Trends in incidence and mortality of early-onset cancer in Germany between 1999 and 2019.","authors":"Dina Voeltz, Kira Baginski, Claudia Hornberg, Annika Hoyer","doi":"10.1007/s10654-024-01143-3","DOIUrl":"10.1007/s10654-024-01143-3","url":null,"abstract":"","PeriodicalId":11907,"journal":{"name":"European Journal of Epidemiology","volume":" ","pages":"839-842"},"PeriodicalIF":7.7,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11343941/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141918604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Serum neurofilament light chain as a prognostic marker of all-cause mortality in a national sample of US adults. 血清神经丝蛋白轻链是美国成年人全因死亡率的预后指标。
IF 7.7 1区 医学
European Journal of Epidemiology Pub Date : 2024-07-01 Epub Date: 2024-05-21 DOI: 10.1007/s10654-024-01131-7
May A Beydoun, Nicole Noren Hooten, Michael F Georgescu, Hind A Beydoun, Shaker M Eid, Marie T Fanelli-Kuczmarski, Michele K Evans, Alan B Zonderman
{"title":"Serum neurofilament light chain as a prognostic marker of all-cause mortality in a national sample of US adults.","authors":"May A Beydoun, Nicole Noren Hooten, Michael F Georgescu, Hind A Beydoun, Shaker M Eid, Marie T Fanelli-Kuczmarski, Michele K Evans, Alan B Zonderman","doi":"10.1007/s10654-024-01131-7","DOIUrl":"10.1007/s10654-024-01131-7","url":null,"abstract":"<p><p>Neurofilament light chain (NfL) is a neuron-specific structural protein released into the extracellular space, including body fluids, upon neuroaxonal damage. Despite evidence of a link in neurological disorders, few studies have examined the association of serum NfL with mortality in population-based studies. Data from the National Health and Nutrition Survey were utilized including 2,071 Non-Hispanic White, Non-Hispanic Black and Hispanic adult participants and adult participants of other ethnic groups (20-85 years) with serum NfL measurements who were followed for ≤ 6 years till 2019. We tested the association of serum NfL with mortality in the overall population and stratified by sex with the addition of potential interactive and mediating effects of cardio-metabolic risk factors and nutritional biomarkers. Elevated serum NfL levels (above median group) were associated with mortality risk compared to the below median NfL group in the overall sample (P = 0.010), with trends observed within each sex group (P < 0.10). When examining Log<sub>e</sub> NfL as a continuum, one standard deviation of Log<sub>e</sub> NfL was associated with an increased mortality risk (HR = 1.88, 95% CI 1.60-2.20, P < 0.001) in the reduced model adjusted for age, sex, race, and poverty income ratio; a finding only slightly attenuated with the adjustment of lifestyle and health-related factors. Four-way decomposition indicated that there was, among others, mediated interaction between NfL and HbA1c and a pure inconsistent mediation with 25(OH)D3 in predicting all-cause mortality, in models adjusted for all other covariates. Furthermore, urinary albumin-to-creatinine ratio interacted synergistically with NfL in relation to mortality risk both on the additive and multiplicative scales. These data indicate that elevated serum NfL levels were associated with all-cause mortality in a nationally representative sample of US adults.</p>","PeriodicalId":11907,"journal":{"name":"European Journal of Epidemiology","volume":" ","pages":"795-809"},"PeriodicalIF":7.7,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11343803/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141070852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Estimating and displaying population attributable fractions using the R package: graphPAF. 使用 R 软件包 graphPAF 估算和显示人口可归因分数。
IF 7.7 1区 医学
European Journal of Epidemiology Pub Date : 2024-07-01 Epub Date: 2024-07-06 DOI: 10.1007/s10654-024-01129-1
John Ferguson, Maurice O'Connell
{"title":"Estimating and displaying population attributable fractions using the R package: graphPAF.","authors":"John Ferguson, Maurice O'Connell","doi":"10.1007/s10654-024-01129-1","DOIUrl":"10.1007/s10654-024-01129-1","url":null,"abstract":"<p><p>Here we introduce graphPAF, a comprehensive R package designed for estimation, inference and display of population attributable fractions (PAF) and impact fractions. In addition to allowing inference for standard population attributable fractions and impact fractions, graphPAF facilitates display of attributable fractions over multiple risk factors using fan-plots and nomograms, calculations of attributable fractions for continuous exposures, inference for attributable fractions appropriate for specific risk factor <math><mo>→</mo></math> mediator <math><mo>→</mo></math> outcome pathways (pathway-specific attributable fractions) and Bayesian network-based calculations and inference for joint, sequential and average population attributable fractions in multi-risk factor scenarios. This article can be used as both a guide to the theory of attributable fraction estimation and a tutorial regarding how to use graphPAF in practical examples.</p>","PeriodicalId":11907,"journal":{"name":"European Journal of Epidemiology","volume":" ","pages":"715-742"},"PeriodicalIF":7.7,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11343908/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141544701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessing the validity of a Parkinson's care evaluation: the PRIME-NL study. 评估帕金森病护理评估的有效性:PRIME-NL 研究。
IF 7.7 1区 医学
European Journal of Epidemiology Pub Date : 2024-07-01 Epub Date: 2024-05-30 DOI: 10.1007/s10654-024-01123-7
Liza M Y Gelissen, Robin van den Bergh, Amir H Talebi, Angelika D Geerlings, Bart R Maas, Myrthe M Burgler, Yvet Kroeze, Agnes Smink, Bastiaan R Bloem, Marten Munneke, Yoav Ben-Shlomo, Sirwan K L Darweesh
{"title":"Assessing the validity of a Parkinson's care evaluation: the PRIME-NL study.","authors":"Liza M Y Gelissen, Robin van den Bergh, Amir H Talebi, Angelika D Geerlings, Bart R Maas, Myrthe M Burgler, Yvet Kroeze, Agnes Smink, Bastiaan R Bloem, Marten Munneke, Yoav Ben-Shlomo, Sirwan K L Darweesh","doi":"10.1007/s10654-024-01123-7","DOIUrl":"10.1007/s10654-024-01123-7","url":null,"abstract":"<p><strong>Introduction: </strong>The PRIME-NL study prospectively evaluates a new integrated and personalized care model for people with parkinsonism, including Parkinson's disease, in a selected region (PRIME) in the Netherlands. We address the generalizability and sources of selection and confounding bias of the PRIME-NL study by examining baseline and 1-year compliance data.</p><p><strong>Methods: </strong>First, we assessed regional baseline differences between the PRIME and the usual care (UC) region using healthcare claims data of almost all people with Parkinson's disease in the Netherlands (the source population). Second, we compared our questionnaire sample to the source population to determine generalizability. Third, we investigated sources of bias by comparing the PRIME and UC questionnaire sample on baseline characteristics and 1-year compliance.</p><p><strong>Results: </strong>Baseline characteristics were similar in the PRIME (n = 1430) and UC (n = 26,250) source populations. The combined questionnaire sample (n = 920) was somewhat younger and had a slightly longer disease duration than the combined source population. Compared to the questionnaire sample in the PRIME region, the UC questionnaire sample was slightly younger, had better cognition, had a longer disease duration, had a higher educational attainment and consumed more alcohol. 1-year compliance of the questionnaire sample was higher in the UC region (96%) than in the PRIME region (92%).</p><p><strong>Conclusion: </strong>The generalizability of the PRIME-NL study seems to be good, yet we found evidence of some selection bias. This selection bias necessitates the use of advanced statistical methods for the final evaluation of PRIME-NL, such as inverse probability weighting or propensity score matching. The PRIME-NL study provides a unique window into the validity of a large-scale care evaluation for people with a chronic disease, in this case parkinsonism.</p>","PeriodicalId":11907,"journal":{"name":"European Journal of Epidemiology","volume":" ","pages":"811-825"},"PeriodicalIF":7.7,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11343810/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141179042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信